REVOLUTION MEDICINES ANNOUNCES U.S. FDA BREAKTHROUGH THERAPY DESIGNATION FOR RASONQUE™ (DARAXONRASIB) IN COMBINATION WITH CHEMOTHERAPY FOR FIRST LINE METASTATIC PANCREATIC CANCER

Reuters · 2d ago

Please log in to view news